AstraZeneca Signs License Agreement With KYM Biosciences for Gastric Cancer Therapy
February 23 2023 - 2:57AM
Dow Jones News
By Michael Susin
AstraZeneca PLC said Thursday that it has entered into an
agreement with KYM Biosciences Inc. regarding an exclusive license
agreement for a gastric cancer treatment.
The Anglo-Swedish pharma major said it will be responsible for
the research, development, manufacture and commercialization of
CMG901 globally.
AstraZeneca will make an upfront payment of $63 million,
additional development and sales-related milestone payments of up
to $1.1 billion to KYM Biosciences and tiered royalties up to low
double digits, it added.
The deal is expected to close in the first half of 2023.
MG901 is currently under a Phase 1 clinical trial for the
treatment of Claudin 18.2-positive solid tumors, including gastric
cancer.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
February 23, 2023 02:42 ET (07:42 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024